一项关于多发性硬化症免疫抑制治疗的国际调查问卷结果。

Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis.

作者信息

Hommes O R, Weiner H L

机构信息

European Charcot Foundation, Nijmegen, The Netherlands.

出版信息

Mult Scler. 2002 Apr;8(2):139-41. doi: 10.1191/1352458502ms791oa.

DOI:10.1191/1352458502ms791oa

PMID:11990871

Abstract

In November 2000, a questionnaire was sent to 702 multiple sclerosis (MS) centers. Data on the institute, treating neurologists, number of MS patients under care, and the number of patients treated with immunosuppressive treatments were collected. The results indicate that overall, around 10% of MS patients are treated with one of four drugs: azathioprine, cyclophosphamide, methotrexate, and mitoxantrone. Azathioprine was most frequently used. More than 30% of MS patients in France are treated with immunosuppressive drugs. In some other countries, these treatments are hardly prescribed.

摘要

2000年11月，一份调查问卷被寄给了702个多发性硬化症（MS）治疗中心。收集了关于机构、主治神经科医生、正在接受治疗的MS患者数量以及接受免疫抑制治疗的患者数量的数据。结果表明，总体而言，约10%的MS患者接受了四种药物之一的治疗：硫唑嘌呤、环磷酰胺、甲氨蝶呤和米托蒽醌。硫唑嘌呤使用最为频繁。法国超过30%的MS患者接受免疫抑制药物治疗。在其他一些国家，这些治疗几乎不被处方。